Wai Yuen Tong Medicine Holdings Limited's (HKG:897) Share Price Boosted 51% But Its Business Prospects Need A Lift Too
Jul 26
Hong Kong (HSI) Pharma Industry Analysis
UpdatedJul 26, 2024
DataAggregated Company Financials
Companies39
- 7D-4.2%
- 3M-6.7%
- 1Y-9.9%
- YTD-11.6%
Over the last 7 days, the Pharma industry has dropped 4.2%, driven by pullbacks in Hansoh Pharmaceutical Group and CSPC Pharmaceutical Group of 2.5% and 3.3%, respectively. Meanwhile, United Laboratories International Holdings actually outperformed within the industry, gaining 9.1% in the last week. However, the industry is down 9.9% over the past year. As for the next few years, earnings are expected to grow by 11% per annum.
Industry Valuation and Performance
Has the Hong Kong Pharma Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Fri, 26 Jul 2024 | HK$417.9b | HK$460.0b | HK$32.6b | 7.4x | 12.8x | 0.9x |
| Sun, 23 Jun 2024 | HK$446.5b | HK$462.1b | HK$33.8b | 7.8x | 13.2x | 1x |
| Tue, 21 May 2024 | HK$490.7b | HK$462.9b | HK$33.7b | 8.8x | 14.6x | 1.1x |
| Thu, 18 Apr 2024 | HK$429.5b | HK$464.6b | HK$33.8b | 7.3x | 12.7x | 0.9x |
| Sat, 16 Mar 2024 | HK$468.3b | HK$470.3b | HK$33.3b | 7.7x | 14.1x | 1x |
| Mon, 12 Feb 2024 | HK$410.1b | HK$471.8b | HK$33.7b | 6.6x | 12.2x | 0.9x |
| Wed, 10 Jan 2024 | HK$465.0b | HK$472.8b | HK$33.8b | 7.7x | 13.7x | 1x |
| Fri, 08 Dec 2023 | HK$475.6b | HK$472.6b | HK$33.8b | 7.5x | 14.1x | 1x |
| Sun, 05 Nov 2023 | HK$489.5b | HK$469.1b | HK$31.9b | 6.9x | 15.4x | 1x |
| Tue, 03 Oct 2023 | HK$436.3b | HK$469.6b | HK$31.6b | 6.8x | 13.8x | 0.9x |
| Thu, 31 Aug 2023 | HK$435.1b | HK$454.9b | HK$30.9b | 7.8x | 14.1x | 1x |
| Sat, 29 Jul 2023 | HK$495.6b | HK$446.8b | HK$27.9b | 9.3x | 17.8x | 1.1x |
| Mon, 26 Jun 2023 | HK$481.3b | HK$447.0b | HK$27.7b | 9.6x | 17.4x | 1.1x |
| Wed, 24 May 2023 | HK$542.2b | HK$449.7b | HK$28.0b | 9.1x | 19.3x | 1.2x |
| Fri, 21 Apr 2023 | HK$570.1b | HK$453.7b | HK$28.8b | 9.1x | 19.8x | 1.3x |
| Sun, 19 Mar 2023 | HK$608.0b | HK$444.4b | HK$34.3b | 10.6x | 17.7x | 1.4x |
| Tue, 14 Feb 2023 | HK$621.1b | HK$446.7b | HK$35.5b | 11.1x | 17.5x | 1.4x |
| Thu, 12 Jan 2023 | HK$638.7b | HK$447.3b | HK$35.6b | 11.8x | 17.9x | 1.4x |
| Sat, 10 Dec 2022 | HK$609.9b | HK$441.7b | HK$34.7b | 10.3x | 17.6x | 1.4x |
| Mon, 07 Nov 2022 | HK$579.4b | HK$436.7b | HK$33.9b | 8.9x | 17.1x | 1.3x |
| Wed, 05 Oct 2022 | HK$501.6b | HK$514.3b | HK$40.0b | 8.8x | 12.5x | 1x |
| Fri, 02 Sep 2022 | HK$563.8b | HK$522.1b | HK$41.2b | 9.9x | 13.7x | 1.1x |
| Sun, 31 Jul 2022 | HK$596.4b | HK$513.1b | HK$51.9b | 8.1x | 11.5x | 1.2x |
| Tue, 28 Jun 2022 | HK$638.5b | HK$514.9b | HK$52.0b | 9.8x | 12.3x | 1.2x |
| Thu, 26 May 2022 | HK$575.9b | HK$514.9b | HK$52.3b | 8.7x | 11x | 1.1x |
| Sat, 23 Apr 2022 | HK$577.4b | HK$522.0b | HK$52.4b | 8.4x | 11x | 1.1x |
| Mon, 21 Mar 2022 | HK$633.0b | HK$502.6b | HK$48.0b | 8.7x | 13.2x | 1.3x |
| Wed, 16 Feb 2022 | HK$685.3b | HK$497.4b | HK$43.9b | 9.7x | 15.6x | 1.4x |
| Fri, 14 Jan 2022 | HK$734.1b | HK$497.1b | HK$43.8b | 9.8x | 16.8x | 1.5x |
| Sun, 12 Dec 2021 | HK$690.3b | HK$496.9b | HK$43.8b | 9.2x | 15.8x | 1.4x |
| Tue, 09 Nov 2021 | HK$653.5b | HK$494.8b | HK$43.3b | 9.1x | 15.1x | 1.3x |
| Thu, 07 Oct 2021 | HK$714.1b | HK$490.5b | HK$42.5b | 9.4x | 16.8x | 1.5x |
| Sat, 04 Sep 2021 | HK$816.9b | HK$489.5b | HK$42.4b | 11.6x | 19.3x | 1.7x |
| Mon, 02 Aug 2021 | HK$911.5b | HK$489.5b | HK$42.4b | 11.8x | 21.5x | 1.9x |
Price to Earnings Ratio
21.5x
Current Industry PE
- Investors are pessimistic on the Hong Kong Pharmaceuticals industry, indicating that they anticipate long term growth rates will be lower than they have historically.
- The industry is trading at a PE ratio of 12.8x which is lower than its 3-year average PE of 15.1x.
- The 3-year average PS ratio of 1.2x is higher than the industry's current PS ratio of 0.91x.
Past Earnings Growth
- The earnings for companies in the Pharmaceuticals industry have declined 8.3% per year over the last three years,
- Revenues have also declined 2.1% per year.
- This means overall sales from these companies are declining and profits are subsequently falling as well.
Industry Trends
Which industries have driven the changes within the Hong Kong Healthcare industry?
| HK Market | -3.89% | |
| Healthcare | -4.81% | |
| Pharma | -4.22% | |
| Pharma | -4.22% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| 3933 United Laboratories International Holdings | HK$8.84 | 9.1% +HK$1.3b | 39.2% | PE5.5x | |
| 2552 Hua Medicine (Shanghai) | HK$1.30 | 7.4% +HK$88.2m | -40.9% | PS15.5x | |
| 3737 Zhongzhi Pharmaceutical Holdings | HK$1.22 | 6.1% +HK$60.5m | 3.4% | PE6x | |
| 2161 JBM (Healthcare) | HK$0.97 | 2.1% +HK$16.6m | -23.0% | PE6.2x | |
| 8329 Shenzhen Neptunus Interlong Bio-technique | HK$0.14 | 5.8% +HK$13.4m | -12.7% | PE8.3x |
